Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.

Livzon Pharmaceutical, Merck & Co and AbbVie helped the immuno-oncology therapy developer take its overall funding to $109m.

Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.

UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Novo helped the cardiac pump developer CorWave secure series C funding to increase its total funding to over $95m.

The newly launched cancer therapy startup plans to initiate clinical trials this year after securing funding from Alexandria Real Estate Equities’ venture arm.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.